Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lixte Biotechnology Holdings, Inc. filings document a clinical-stage oncology issuer developing cancer treatments through LB-100, Liora Technologies Europe and related platform assets. Annual and periodic disclosure categories cover operating and financial results, clinical and regulatory matters, capital structure, governance and the company's single reportable development segment.
Material-event filings record definitive agreements, subsidiary-level consulting and allocation arrangements, compensation changes, stock option cancellations, restricted share unit awards under the 2020 Stock Incentive Plan, and other capital-structure matters. Proxy materials cover shareholder voting, board governance and executive-compensation disclosures.
LIXTE Biotechnology Holdings, Inc. signed a definitive Merger Agreement to acquire 100% of NOMAD Transportable Power Systems, a leader in mobile, utility-grade battery energy storage systems. Merger Sub will merge into NOMAD, which will become a wholly owned subsidiary, and the combined company plans to be renamed NOMAD Power Solutions.
At closing, NOMAD stockholders will receive a pro rata share of up to 50,500 shares of Series D Convertible Preferred Stock, with a $1,000 original issue price per share and convertible into up to 50,500,000 shares of common stock at $1.00 per share, plus up to 3,000,000 shares of common stock. The preferred stock will be non-voting until stockholders approve its conversion and an increase in authorized shares.
The merger is subject to conditions, including LIXTE having at least $16.5 million in unrestricted cash, Nasdaq listing of the Exchange Common Shares, and board changes adding NOMAD designees. NOMAD has shown rapid growth, with management citing approximately 175% revenue growth in 2025 and a projected approximately 135% increase in 2026, driven by strong demand for mobile, utility-grade BESS.
Lixte Biotechnology Holdings reports that Strategic EP, LLC and Alexander Chase Deitch together beneficially own 5.1% (774,902 shares) of Common Stock. The filing states the percentage is based on June 2, 2026 outstanding share count of 15,278,806, as reported in the Issuer's Prospectus on Form 424B5 filed June 4, 2026. The disclosure notes 545,521 warrants are issuable but contain a provision preventing exercise to the extent it would push ownership above 4.99%. The Reporting Persons filed a Joint Filing Agreement and signed the Schedule 13G on June 9, 2026.
Lixte Biotechnology Holdings, Inc. completed a registered direct offering of 2,366,503 shares of common stock and Pre-Funded Warrants to purchase 258,859 shares, generating gross proceeds of approximately $16.6 million before expenses. The securities were priced at $6.31 per share of common stock and $6.30 per Pre-Funded Warrant.
The Pre-Funded Warrants are immediately exercisable at $0.0001 per share and remain exercisable until fully exercised. The transaction, conducted under an effective shelf registration statement on Form S-3, closed on June 4, 2026, and the company plans to use the net proceeds for general corporate purposes and working capital.
Lixte is offering 2,366,503 shares of Common Stock and 258,859 Pre-Funded Warrants at $6.31 each. The offering is expected to close on or about June 4, 2026 and is intended to raise approximately $16,566,027.20 in gross proceeds. The Company states it will use net proceeds for working capital and general corporate purposes, including further clinical development of its lead compound, LB-100. Assuming exercise of the Pre-Funded Warrants, the prospectus shows 15,278,806 shares of Common Stock outstanding as of June 2, 2026.
Porter Stuart D reported acquisition or exercise transactions in this Form 4 filing.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Stuart D. Porter reported receiving an equity grant of 25,000 shares of common stock in the form of restricted share units. The grant was made at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase.
The 25,000 RSUs were granted under the company’s 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter until fully vested. Following this grant, Porter directly holds 25,000 shares.
LIXTE Biotechnology Holdings, Inc. filed a regulatory ownership report identifying Stuart D Porter as a director. The provided data shows no reported transactions, no derivative positions, and no share movements, with all transaction counts and share amounts listed as zero.
LIXTE Biotechnology Holdings is undertaking a major strategic shift, repositioning itself as an AI energy infrastructure equipment and services platform focused on supplying power solutions for AI and hyperscale data centers. The company highlights a widening gap between North American electricity demand and generation capacity, citing a projected 224 gigawatt increase in summer peak demand over the next decade and recent reliability alerts to frame the opportunity.
As part of this transformation, LIXTE plans to seek a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations that are developing cancer therapies and proton therapy systems. The company expects to maintain its Nasdaq listing under the symbol LIXT while it executes this pivot and pursues strategic acquisitions and partnerships in advanced generation technologies.
LIXTE also appointed Stuart D. Porter to its Board of Directors, effective May 29, 2026, with a term expiring at the 2026 annual meeting. Porter is the Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital, with over 29 years of senior investment experience and oversight of more than $12 billion of invested and committed capital across energy and energy-transition sectors, including a roughly 10 gigawatt pipeline of AI data-center-oriented power generation opportunities.
Lixte Biotechnology Holdings reported a larger quarterly loss as it continues to advance its cancer drug and proton therapy programs without generating revenue. For the three months ended March 31, 2026, the company recorded a net loss of $1.99 million, compared with $0.71 million a year earlier, driven mainly by higher general and administrative costs of $1.65 million and research and development spending of $0.33 million. Cash declined to $3.25 million from $5.11 million at December 31, 2025, and management concluded there is substantial doubt about its ability to continue as a going concern without additional financing. The balance sheet now includes the LiGHT proton therapy system at a carrying value of $6.61 million and a related operating lease liability of $1.06 million, reflecting the 2025 acquisition of Liora Technologies Europe Ltd. All Series B Convertible Preferred Stock was converted into common stock, increasing shares outstanding to 11.63 million at March 31, 2026. Lixte remains focused on clinical trials of its lead compound LB‑100 and on recommissioning the LiGHT system, while noting it must raise additional capital to fund planned clinical and proton therapy activities.
Lixte Biotechnology CEO Geordan Garrett Pursglove restructured his equity compensation on April 15, 2026. He agreed to cancel 350,000 options to purchase common stock with a $2.83 exercise price that were scheduled to expire on July 3, 2030, returning them to the company.
In exchange, he received 350,000 shares of common stock as a grant or award tied to 350,000 restricted share units under the 2020 Stock Incentive Plan. These RSUs vest immediately upon grant, so he now directly holds 350,000 common shares after the transaction. The filing shows no open‑market buying or selling; it is an issuer disposition of options paired with a compensatory stock award.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Chief Financial Officer Peter Stazzone restructured his equity compensation on April 15, 2026. He agreed to cancel 50,000 stock options with a $4.45 exercise price in exchange for 50,000 restricted stock units granted the same day.
Each RSU represents a contingent right to receive one share of common stock, and all 50,000 RSUs vested immediately upon grant, leaving him with 50,000 shares of common stock held directly after the transactions. No open‑market buying or selling occurred; these were compensation-related adjustments between the executive and the company.